Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

As of December 31, 2024, the company had cash, cash equivalents and investments of $184.6M, which is expected to fund operating expenses and ...

The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner yielding ...